Siemens Fonds Invest GmbH cut its stake in shares of CVS Health Co. (NYSE:CVS – Get Rating) by 3.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 64,086 shares of the pharmacy operator’s stock after selling 2,105 shares during the quarter. Siemens Fonds Invest GmbH’s holdings in CVS Health were worth $5,972,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. Lowe Brockenbrough & Co. Inc. boosted its position in shares of CVS Health by 3.4% in the 4th quarter. Lowe Brockenbrough & Co. Inc. now owns 111,052 shares of the pharmacy operator’s stock worth $10,349,000 after buying an additional 3,646 shares in the last quarter. Silvercrest Asset Management Group LLC lifted its holdings in CVS Health by 0.9% in the 4th quarter. Silvercrest Asset Management Group LLC now owns 1,382,260 shares of the pharmacy operator’s stock valued at $128,813,000 after purchasing an additional 12,377 shares in the last quarter. Engineers Gate Manager LP lifted its holdings in CVS Health by 533.9% in the 4th quarter. Engineers Gate Manager LP now owns 16,469 shares of the pharmacy operator’s stock valued at $1,535,000 after purchasing an additional 13,871 shares in the last quarter. Paradigm Asset Management Co. LLC purchased a new position in CVS Health in the 4th quarter valued at about $3,998,000. Finally, Qtron Investments LLC lifted its holdings in shares of CVS Health by 14.2% during the 4th quarter. Qtron Investments LLC now owns 11,431 shares of the pharmacy operator’s stock worth $1,065,000 after acquiring an additional 1,422 shares during the period. 77.29% of the stock is owned by institutional investors and hedge funds.
In other news, CEO Karen S. Lynch acquired 14,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 3rd. The shares were purchased at an average price of $69.75 per share, for a total transaction of $976,500.00. Following the completion of the acquisition, the chief executive officer now owns 431,392 shares of the company’s stock, valued at approximately $30,089,592. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.25% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on CVS shares. UBS Group cut their price objective on shares of CVS Health from $102.00 to $94.00 in a report on Tuesday, May 2nd. Royal Bank of Canada reissued an “outperform” rating and set a $115.00 target price on shares of CVS Health in a research report on Thursday, February 9th. Sanford C. Bernstein dropped their target price on shares of CVS Health from $107.00 to $93.00 in a research report on Tuesday, May 2nd. StockNews.com raised shares of CVS Health from a “hold” rating to a “buy” rating in a research report on Tuesday, May 16th. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of CVS Health in a research report on Monday, April 10th. They issued a “hold” rating for the company. Two analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $108.20.
CVS Health Price Performance
NYSE CVS traded up $0.01 on Friday, reaching $71.76. The company’s stock had a trading volume of 4,523,911 shares, compared to its average volume of 8,843,495. CVS Health Co. has a twelve month low of $66.34 and a twelve month high of $107.26. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.67 and a current ratio of 0.92. The stock has a market cap of $92.00 billion, a PE ratio of 23.68, a PEG ratio of 1.30 and a beta of 0.63. The firm’s 50 day moving average is $71.81 and its two-hundred day moving average is $82.91.
CVS Health (NYSE:CVS – Get Rating) last posted its quarterly earnings data on Wednesday, May 3rd. The pharmacy operator reported $2.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.07 by $0.13. The firm had revenue of $85.28 billion for the quarter, compared to the consensus estimate of $80.67 billion. CVS Health had a return on equity of 15.75% and a net margin of 1.20%. The business’s revenue for the quarter was up 11.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.22 EPS. As a group, sell-side analysts predict that CVS Health Co. will post 8.62 EPS for the current year.
CVS Health Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Monday, May 1st. Stockholders of record on Friday, April 21st were issued a $0.605 dividend. The ex-dividend date was Thursday, April 20th. This represents a $2.42 dividend on an annualized basis and a dividend yield of 3.37%. CVS Health’s dividend payout ratio is 79.87%.
CVS Health Company Profile
CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Pharmacy Services, Retail or Long-Term Care, Health Care Benefits, and Corporate and Other. The Pharmacy Services segment focuses on the pharmacy benefit management solutions.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider CVS Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and CVS Health wasn’t on the list.
While CVS Health currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you’ll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.